Osiris Therapeutics Inc (NASDAQ:OSIR)

17.27
Delayed Data
As of Feb 27
 -0.07 / -0.40%
Today’s Change
11.80
Today|||52-Week Range
17.69
+8.01%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$592.7M

Company Description

Osiris Therapeutics, Inc. is a stem cell company, which focuses on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular, orthopedic and wound healing markets. The company operates its business through two segments: Therapeutics and Biosurgery segment. The Therapeutics segment focuses on developing biologic stem cell drug candidates from readily available and non-controversial sources. The segment, using mesenchymal stem cell technology offers two biologic drug candidates, Prochymal and Chondrogen which has anti-inflammatory properties. The Biosurgery segment works to harness the ability of cells and novel constructs to promote the body's natural healing. The segment manufactures, markets and distributes Grafix and Ovation for tissue repair. Osiris Therapeutics was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD.

Contact Information

Osiris Therapeutics, Inc.
7015 Albert Einstein Drive
Columbia Maryland 21046-1707
P:(443) 545-1800
Investor Relations:

Employees

Shareholders

Individual stakeholders44.67%
Mutual fund holders13.49%
Other institutional12.14%

Top Executives

Lode DebrabanderePresident, Chief Executive Officer, COO & Director
Philip R. JacobyChief Financial Officer, Secretary & Treasurer
Alla DanilkovitchVice President-Research & Development
Douglas JacobsteinSenior Medial Director
Jonathan Mark HopperChief Medical Officer

To view my watchlist

Not a member yet?

Sign up now for a free account